Bibliography
- Van A. Trinh & Wen-Jen Hwu: Ipilimumab in the Treatment of Melanoma. Expert Opin Biol Ther 2012;12(6):773-82
- Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
- Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
- Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
- Wang W, Lau R, Yu D, PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25(Hi) regulatory T cells. Int Immunol 2009;21:1065-77
- Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti-tumor T cell responses. J Cell Biochem 2007;102:301-10
- Morton DL, Mozzillo N, Thompson JF, MMAIT Clinical Trials Group. An inter-national, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007;25(Suppl):8508
- Hauschild A, Weichenthal M, Balda B-R, Prospective-randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinical detectable node metastasis. J Clin Oncol 2003;21:2883-8
- Huang RR, Jalil J, Economou JS, CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011;17:4101-9
- Lebbe C, O'Day S, Chiarion Sileni V, Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma. Oral abstract O-015. Perspectives in Melanoma XII. 2008